Cargando…
High miR-26a and low CDC2 levels associate with decreased EZH2 expression and with favorable outcome on tamoxifen in metastatic breast cancer
For patients with metastatic breast cancer, we previously described that increased EZH2 expression levels were associated with an adverse outcome to tamoxifen therapy. Main objective of the present study is to investigate miR-26a and miR-101 levels, which both target EZH2, for their association with...
Autores principales: | Jansen, M. P. H. M., Reijm, E. A., Sieuwerts, A. M., Ruigrok-Ritstier, K., Look, M. P., Rodríguez-González, F. G., Heine, A. A. J., Martens, J. W., Sleijfer, S., Foekens, J. A., Berns, E. M. J. J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3387494/ https://www.ncbi.nlm.nih.gov/pubmed/22094936 http://dx.doi.org/10.1007/s10549-011-1877-4 |
Ejemplares similares
-
CYP2C19*2 predicts substantial tamoxifen benefit in postmenopausal breast cancer patients randomized between adjuvant tamoxifen and no systemic treatment
por: Beelen, K., et al.
Publicado: (2013) -
Relevance of BCAR4 in tamoxifen resistance and tumour aggressiveness of human breast cancer
por: Godinho, M F E, et al.
Publicado: (2010) -
The prognostic and predictive value of ESR1 fusion gene transcripts in primary breast cancer
por: Vitale, Silvia R., et al.
Publicado: (2022) -
Mitochondrial DNA content in breast cancer: Impact on in vitro and in vivo phenotype and patient prognosis
por: Weerts, Marjolein J.A., et al.
Publicado: (2016) -
DC-SCRIPT is a novel regulator of the tumor suppressor gene CDKN2B and induces cell cycle arrest in ERα-positive breast cancer cells
por: Ansems, Marleen, et al.
Publicado: (2015)